Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of HR20013 for injection for prevention of
chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy.